Skip to content
  • Home
  • Media
  • News
  • LEO Pharma appoints Paul Navarre new member of its Board of Directors

LEO Pharma appoints Paul Navarre new member of its Board of Directors

Ballerup, Denmark, August 31, 2022 – LEO Pharma today announced the appointment of Paul Navarre as new member of its Board of Directors.
Paul Navarre currently serves as chairman of the Board of Directors at HTL (dermatology) and Arkopharma (Dietary Supplements), as Vice Chairman of Hallura (dermatology) and as Strategic Advisor to other companies. From 2017-2020 he held the position as CEO of Ferring US Holding subsequent to ten years at Allergan, among other as President of International Operations (global except US) and President of EAME (Europe, Middle East and Africa). Prior to that, he spent 15 years at Procter & Gamble managing multiple countries and global brands in pharmaceuticals and Health and beauty care.

Paul Navarre has a solid track record of delivering sustainable top line growth and building high performance organizations in the specialty pharmaceutical business through scientific innovation and customer centric approaches.

With his impressive career, Paul brings extensive strategic and commercial experience from the global biotech and dermatology market, that will be of great value to LEO Pharma in its ambitions to create future growth and become a top five company within medical dermatology. I am excited to be working together with Paul going forward”, said Jesper Brandgaard, chairman of the Board of Directors at LEO Pharma.

It’s a privilege to join the Board of Directors at LEO Pharma at this time in the company’s history. With its ongoing transformation, many steps have already been taken to position the company for future growth and I look much forward to being part of continuing this development”, said Paul Navarre.

Paul Navarre was elected one of the Top 100 Most Inspiring People by PharmaVoice in 2019. In 2021 he completed the Insead Corporate Governance Course.

About LEO Pharma


LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,200 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.



Henrik Heskjaer

Director, Global External Communications
Tel: +45 3140 6180